Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
PA Konstantinopoulos, S Waggoner, GA Vidal… - JAMA …, 2019 - jamanetwork.com
Importance Patients with recurrent ovarian carcinoma frequently develop resistance to
platinum-based chemotherapy, at which time treatment options become limited. Objective To
evaluate the poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib
combined with pembrolizumab in patients with recurrent ovarian carcinoma. Design, Setting,
and Participants The TOPACIO/KEYNOTE-162 (Niraparib in Combination With
Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an …
platinum-based chemotherapy, at which time treatment options become limited. Objective To
evaluate the poly (adenosine diphosphate–ribose) polymerase (PARP) inhibitor niraparib
combined with pembrolizumab in patients with recurrent ovarian carcinoma. Design, Setting,
and Participants The TOPACIO/KEYNOTE-162 (Niraparib in Combination With
Pembrolizumab in Patients With Triple-Negative Breast Cancer or Ovarian Cancer) trial, an …